Capricor Therapeutics Stock Skyrockets Over 340% On Positive Phase 3 HOPE-3 Trial Results

(RTTNews) - Capricor Therapeutics, Inc. (CAPR) shares surged 342.30 percent, rising $21.77 to $28.13 on Wednesday after announcing positive topline data from its pivotal Phase 3 HOPE-3 trial of Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. The study showed statistically significant improvements in both skeletal and cardiac function, reinforcing durability seen in previous HOPE-2 studies.

Capricor is trading at $28.13, compared with a previous close of $6.36 on the Nasdaq. The stock opened at $30.00 and has traded between $21.50 and $40.37 so far today, with volume at 39.80 million shares.

The company's 52-week range is $4.30 to $40.37.